News

An analysis of Medicare patients with follicular lymphoma revealed which characteristics correlated with overall survival.

John Nakayama, MD, discusses what the evolution of endometrial cancer treatment has looked like in recent years.

Emerging data demonstrate the potential of these drugs to optimize survival, preserve quality of life, and even spare patients a radical cystectomy.

An analysis of data from the CheckMate-648 trial sows that while adding nivolumab to either ipilimumab or chemotherapy for patients with advanced esophageal squamous cell carcinoma improves survival outcomes, their current price is not cost-effective for first-line treatment.

Significant differences in the incidence of genitourinary events, depression, and ischemic and thrombotic events were observed based on race among patients with prostate cancer after receiving androgen deprivation therapy.

Emerging treatments, particularly claudin 18.2, a potential new biomarker in the HER2-negative gastric and gastroesophageal junction cancer space, were highlights of the 2023 ASCO Gastrointestinal Cancers Symposium.

The new DNA methylation-based PDACatch assay has received a breakthrough device designation from the FDA to detect patients at high-risk for pancreatic adenocarcinoma.

Looking at real-world data, researchers identified a large increase of biomarker testing for patients with early-stage non–small cell lung cancer, which indicates a continuing trend toward personalized treatment.

According to findings from an integrated BIM, single treatment with selpercatinib had a little impact on third-party payers’ formulary budgets for patients with RET-altered solid tumors.

Findings from a survey found that many physicians used new strategies to manage their patients during the COVID-19 pandemic, some of which, such as the use of telehealth, are expected to continue into the future.

New results from ORIENT-31 show a sustained progression-free survival benefit and overall survival improvement trend in patients with EGFR-mutant non–small cell lung cancer who failed a tyrosine kinase inhibitor previously.

Two genetically engineered gamma-delta T-cell therapies, INB-400 and INB-410, have been granted an orphan drug designation from the FDA for numerous types of malignant glioma.

A study looked into what drives patient preference for treatment with certain BRAF/MEK inhibitors for BRAF V600E/K-mutant melanoma.

Treatment with lurbinectedin is cost-effective as a second-line treatment for patients with metastatic small cell lung cancer who have had disease progression on or after platinum-based chemotherapy.

Ashish Saxena, MD, explains the outcomes of the addition of immune checkpoint blockade to standard chemotherapy for patients with metastatic small cell lung cancer.

Adjuvant chemotherapy did not lead to survival improvements vs standard chemoradiotherapy alone in patients with locally advanced cervical cancer and resulted in more severe adverse events, according to OUTBACK trial data.

In an interview with Targeted Oncology, Adam J. Olszewski, MD, discussed mosunetuzumab and the rationale and findings of this phase 1b/2 study assessing the agent in elderly patients with diffuse large B-cell lymphoma.

Patients with recurrent or metastatic squamous cell carcinoma of the head and neck did not derive an overall response rate benefit with nivolumab and ipilimumab vs nivolumab alone.

The FoundationOne® Liquid CDx has been granted approval by the FDA as a companion diagnostic for mobocertinib for patients with locally advanced or metastatic non–small cell lung cancer harboring an EGFR exon 20 insertion mutation.

Results from the phase 3 QuANTUM-First study create a position for quizartinib plus chemotherapy in the FLT3-ITD-positive acute myeloid leukemia armamentarium.

Yann-Alexandre Vano, MD, explains some of the findings from the phase 2 BIONIKK trial which evaluated nivolumab and ipilimumab in metastatic renal cell carcinoma.

Impressive efficacy data and consistent safety data continue to be seen with mirvetuximab soravtansine for the treatment of patients with platinum-resistant ovarian cancer, according to data from the confirmatory MIRASOL trial.

Artificial intelligence and machine learning dramatically alter how medicine is practiced, and cancer detection is no exception, according to Toufic Kachaamy, MD of City of Hope Phoenix.

In an interview with Targeted Oncology, Mitchell Smith, MD, PhD, discussed what the findings from the ECOG-ACRIN E1411 trial in patients with mantle cell lymphoma means for the future of the space, and where research is heading.

TPST-1120 shows promising efficacy and safety data in a phase 1b/2 study of the agent among patients with unresectable or metastatic hepatocellular carcinoma.

The TRANSCEND FL and TRANSCEND NHL 001 studies of lisocabtagene maraleucel met its primary end point of overall response rate and secondary end point of complete response rate in patients with follicular lymphoma and B-cell non-Hodgkin lymphoma.

Martin Dreyling, MD, discusses the next steps for research with ibrutinib in the mantle cell lymphoma space following the presentation of data from the phase 3 TRIANGLE study.

It was announced that the phase 3 EMBARK study met its primary end point in patients with nonmetastatic castration-sensitive prostate cancer with high-risk biochemical recurrence.

Treatment with TARA-002 at 3 different dose levels was generally well-tolerated, and no dose limiting toxicities were observed among patients with high-grade non-muscle invasive bladder cancer.

Here is a look back at all of the FDA happenings from April 2023.